Applied Genetic Technologies Corporation

Paratus Sciences Appoints Theresa Heah, M.D., M.B.A. as Chief Executive Officer

Retrieved on: 
Wednesday, February 21, 2024

“We are thrilled to have Dr. Heah assume the helm at Paratus,” said Amir Nashat, Executive Partner of Polaris Partners, chair of Paratus’s Board of Directors and the company’s founding CEO.

Key Points: 
  • “We are thrilled to have Dr. Heah assume the helm at Paratus,” said Amir Nashat, Executive Partner of Polaris Partners, chair of Paratus’s Board of Directors and the company’s founding CEO.
  • “Theresa brings a tremendous wealth of experience as a seasoned pharma and biotech executive, having spearheaded the development and commercialization of multiple innovative therapies.
  • She most recently served as the Chief Executive Officer and President of Intergalactic Therapeutics, a non-viral gene therapy platform company.
  • Under Amir’s leadership, Paratus has made important progress advancing this premise into a state-of-the-art R&D engine.

Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

Retrieved on: 
Thursday, February 8, 2024

“We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.

Key Points: 
  • “We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • Under her strong leadership, Vigil has evolved from inception through IPO, to an organization with two clinical-stage development programs.
  • Dr. Magovčević-Liebisch has served on the Board of Directors of Absci, Aeglea Therapeutics and Applied Genetic Technologies Corporation.
  • I look forward to working with Peter, the board, and the executive team to develop multiple promising drug candidates to improve patient lives.”

Annual Results – Momentum Building on our Commercial Plans

Retrieved on: 
Wednesday, August 30, 2023

Our commitment to transforming healthcare through personalized genetic insights continues driving meaningful advancements, revolutionizing medical practices across the globe.

Key Points: 
  • Our commitment to transforming healthcare through personalized genetic insights continues driving meaningful advancements, revolutionizing medical practices across the globe.
  • Highlighting our commercial progress, the company announces revenues for the 12 months ending June 30, 2023, of A$8.686million, an increase of +A$1.891m; +28% compared with 2022.
  • Momentum building - Growth and Partnerships:
    The dedication of our team, and the power of geneType, have ignited a revolution in healthcare.
  • We are seeing encouraging growth in our commercial volumes for geneType, a testament to the value and trust we are building in the medical community.

APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer

Retrieved on: 
Monday, August 28, 2023

Dr. Shearman, who holds a Ph.D. in neuroscience, has extensive experience in pharmaceutical research, drug development and strategic partnerships.

Key Points: 
  • Dr. Shearman, who holds a Ph.D. in neuroscience, has extensive experience in pharmaceutical research, drug development and strategic partnerships.
  • Prior to APRINOIA, he held executive leadership positions at Editas Medicine, Applied Genetic Technologies Corporation, Merck KGaA and Merck & Co., and has served as Chair of APRINOIA’s Scientific Advisory Board since 2015.
  • “It is a great honor to assume the post of CEO of APRINOIA.
  • APRINOIA is focusing on tauopathies and synucleinopathies, that affect approximately 50 million and 10 million people worldwide, respectively.

Newsweek Names Zebra Technologies to 2023 Top 100 Global Most Loved Workplaces

Retrieved on: 
Tuesday, June 6, 2023

“At Zebra, we prioritize attracting, retaining and developing the greatest asset to our company – our people,” said Jeff Schmitz, Chief People Officer, Zebra Technologies.

Key Points: 
  • “At Zebra, we prioritize attracting, retaining and developing the greatest asset to our company – our people,” said Jeff Schmitz, Chief People Officer, Zebra Technologies.
  • “The companies featured on the 2023 Global Most Loved Workplaces list embody this transformative spirit, proving that when companies prioritize their people, success naturally follows."
  • This year’s featured companies on the Most Loved Workplace list exemplify this principle, even globally.”
    For the full Newsweek list of 2023’s Global Top 100 Most Loved Workplaces, please visit https://www.newsweek.com/rankings/global-most-loved-workplaces-2023 .
  • Zebra Technologies ranked #66 among the top 100 companies named to Newsweek’s inaugural list of Most Loved Workplaces globally.

Zebra Technologies to Release Fourth Quarter and Full Year Results on Feb. 16

Retrieved on: 
Thursday, February 2, 2023

Zebra Technologies Corporation (NASDAQ: ZBRA), an innovator at the edge of the enterprise with solutions and partners that enable businesses to gain a performance edge, will report its fourth quarter and full year 2022 financial results on Thursday morning, Feb. 16, 2023.

Key Points: 
  • Zebra Technologies Corporation (NASDAQ: ZBRA), an innovator at the edge of the enterprise with solutions and partners that enable businesses to gain a performance edge, will report its fourth quarter and full year 2022 financial results on Thursday morning, Feb. 16, 2023.
  • The company will also host a conference call to discuss these results on the same day at 7:30 a.m. CT (8:30 a.m.
  • To access the live webcast of the presentation, visit the events section of the company’s website at investors.zebra.com .
  • The webcast will be archived and available there for at least one year following the call.

Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer

Retrieved on: 
Friday, January 6, 2023

BOSTON, Jan. 6, 2023 /PRNewswire/ -- Intergalactic Therapeutics , a company focused on transforming medicine through non-viral gene therapy, announced today the appointment of Theresa G.H.

Key Points: 
  • BOSTON, Jan. 6, 2023 /PRNewswire/ -- Intergalactic Therapeutics , a company focused on transforming medicine through non-viral gene therapy, announced today the appointment of Theresa G.H.
  • Heah, M.D., M.B.A., as Chief Executive Officer (CEO).
  • Dr. Ehlers, who is Chief Scientific Officer of Apple Tree Partners (ATP) and a Venture Partner at the firm, was the founding CEO of Intergalactic Therapeutics and led its incubation.
  • At ATP, he has led investments in ATP portfolio companies including Ascidian Therapeutics, Aulos Bioscience, Intergalactic Therapeutics, and Replicate Bioscience.

GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes

Retrieved on: 
Tuesday, December 6, 2022

The study used advanced statistical techniques to develop polygenic risk scores for coronary artery disease, hypertension, atrial fibrillation, stroke and type 2 diabetes.

Key Points: 
  • The study used advanced statistical techniques to develop polygenic risk scores for coronary artery disease, hypertension, atrial fibrillation, stroke and type 2 diabetes.
  • The cutting-edge study design meant that the polygenic risk scores developed by GTG use just the genetic changes essential to predict risk without sacrificing predictive performance compared with polygenic risk scores that use up to 820 times the number of genetic changes.
  • GTG quantified the true effects of the polygenic risk scores in predicting disease by accounting for age and sex in the study design.
  • The company’s Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals.

Aurion Biotech Appoints Jonathan Sparks, JD, PhD as Chief Legal Officer

Retrieved on: 
Wednesday, December 7, 2022

Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Dr. Jonathan Sparks as chief legal officer.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Dr. Jonathan Sparks as chief legal officer.
  • View the full release here: https://www.businesswire.com/news/home/20221207005300/en/
    We are delighted to welcome Jon to Aurion Biotech, said Greg Kunst, chief executive officer.
  • In addition to his role at Aurion, Dr. Jonathan Sparks is also a partner and chair of the Intellectual Property practice at McCarter & English, LLP.
  • Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech.

Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation

Retrieved on: 
Thursday, December 1, 2022

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC or the Company) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the Offer) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (Syncona).

Key Points: 
  • GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC or the Company) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the Offer) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (Syncona).
  • The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware.
  • As a result of the merger, AGTC has become an indirect, wholly owned subsidiary of Syncona Limited.
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.